Pharmacologic cardiovascular support.
The availability of newer and better inotropic agents has led to their widespread application in critically ill medical and surgical patients. Although the elective use of inotropic drugs has been associated with adverse outcomes in patients with cardiomyopathy and chronic heart failure, inotropic drugs used as part of treatment protocols designed to optimize oxygen delivery to tissues have been shown to improve outcome in critical illness. Future research must be aimed toward better definition of clinical settings in which outcome can be improved with inotropes and toward identifying safer agents with fewer adverse side effects.
Department of Anesthesia/Critical Care, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
G P
GP
Zaloga
R C
RC
Prielipp
J F
JF
Butterworth
R L
RL
Royster
D000818:Animals; D006348:Cardiac Surgical Procedures; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016638:Critical Illness; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology; D012769:Shock / Q000188:drug therapy / Q000503:physiopathology
D002316:Cardiotonic Agents